Movetis

FlandersBio on Twitter

Biotech company Ablynx wins European Mediscience Award: http://tiny.cc/knen6

posted 1 month ago

Social Media

Life Sciences Database

in het nederlands

FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.

Website: http://www.movetis.com
Email:
Phone: +32 14 40 43 90
FlandersBio Member
More address details

Business Focus

Movetis aims to be valued as a leading GI Specialty pharma company by patients and physicians for our expertise and innovation in the discovery, development and commercialisation of proprietary and differentiated drugs for underserved gastrointestinal diseases with a high unmet medical need. Movetis’ lead compound, Resolor (prucalopride), was approved for commercialisation in the European Economic Area (EEA) for the symptomatic treatment of chronic constipation (CC) in women in whom laxatives fail to provide adequate relief.

Company Profile

Movetis has a broad GI portfolio: Resolor® (prucalopride) is approved in the EEA for the indication “symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief” and the marketing authorisation application is furthermore under review in Switzerland; two products are in Phase II development and Movetis has two prioritised compounds in preclinical development, all addressing important GI areas including ascites, paediatric reflux, refractory GERD (gastroesophageal reflux disease) and severe forms of irritable bowel syndrome.
In addition, Movetis has rights to a large library of qualified lead compounds with potential for development in different GI indications and access to know how for compounds in secretory diarrhoea.
The current portfolio is licensed from Janssen Pharmaceutica NV, Belgium and Ortho-McNeil Pharmaceutical Inc., two Johnson & Johnson companies.

In December 2006, Movetis secured 60 million Euros in a series 'A' financing from J&J, and major European and US. The funds were used to complete the development and registration filing of prucalopride and to continue preclinical and clinical development of the company’s other products.

In 2007 and 2008, Movetis received over three million Euros from the Flemish government to support its discovery efforts.

December 2009 Movetis successfully completed its Initial Public Offering (IPO) raising a total of 97.75 million Euros. Movetis shares are listed on Euronext Brussels. The company began trading as of 4th December 2009, under the ticker symbol MOVE

Science & Technology or Services

MOVETIS is developing a portfolio of eight products and two discovery platforms which address important areas of unmet medical need, including severe chronic constipation, ascites, pediatric reflux, diabetic gastropathy and severe forms of dyspepsia.

Product description

Resolor® (prucalopride), the lead product:

The compound was successfully tested in more than 3000 patients and three identical Phase III trials in constipation support that the product has a good safety and efficacy profile.
In the EU, nearly 14 million patients visit their doctors for chronic constipation and of these, an estimated 7 million patients are dissatisfied with laxative treatment. Of these 7 million, approximately 6 million or 85% are women.
The compound was launched January 27, 2010 on the German market. Movetis is preparing the commercial launch of Resolor in the UK for the second quarter of 2010.

M0002 is a compound that is being developed for the treatment of ascites.

M0002 represents a new class of compounds or aquaretics that produce profound diuresis without loss of electrolytes. The compound is expected to help an estimated 1.5 million patients worldwide that do not satisfactorily respond to current standard of care, diuretics and paracenthesis.
Trial results to date show that M0002 is well tolerated in healthy volunteers and patients. There was no interaction with commonly used diuretics.

M0003 is being developed for symptomatic treatment of heartburn and regurgitation in patients, refractory to PPIs as well as paediatric reflux.

An estimated 800,000 children suffer from severe paediatric reflux primarily caused by impaired motility that requires drug treatment. The official ESPGHAN guidelines position prokinetics as standard of care in this specific population.

Alliances

Janssen Pharmaceutica: The companies entered into a license agreement to develop and commercialize a portfolio of products. Movetis has exclusive rights in its territory for Resolor. Johnson & Johnson has specific rights for specific regions on the earlier portfolio.
Ortho McNeil: The companies entered into a license agreement to develop and commercialize M0002. Movetis has exclusive rights.